PTC
BBIO icon

Private Trust Company’s BridgeBio Pharma BBIO Stock Holding History

Private Trust Company’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$965 Buy
+13
New +$942 ﹤0.01% 2490
2025
Q4 		– Sell
-83
Closed -$4.31K – 2553
2025
Q3 		$4.31K Buy
+83
New +$4.05K ﹤0.01% 2188

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Private Trust Company's BBIO Position: Q1 2026 in Review

Private Trust Company opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 13 shares worth $965. The stake represents ﹤0.01% of the portfolio and ranks #2490 among its holdings. This is a return to the name: Private Trust Company previously reported a position in BBIO as recently as Q3 2025.

Private Trust Company first reported a position in BBIO in Q3 2025 and has held it in 2 quarters since. The position peaked at $4.31K in Q3 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Private Trust Company held 13 shares of BridgeBio Pharma worth $965 as of Q1 2026.
  • BridgeBio Pharma was a new Private Trust Company position in Q1 2026.
  • BridgeBio Pharma made up ﹤0.01% of Private Trust Company's portfolio in Q1 2026, its #2490 holding.
  • Private Trust Company first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 2 quarters since.
  • Private Trust Company's BridgeBio Pharma position peaked at $4.31K in Q3 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Private Trust Company's 13F filing for Q1 2026, filed 30 Apr 2026.